ABO-Group Environment Halfjaarcijfers 2026

ABO-Group posted 1H26 revenue of €54.6 million, up 1.8% organically, but reported a €3.5 million net loss versus a €0.2 million profit a year earlier after €3.6 million of one-off impairments tied to the closure of a Dutch environmental-drilling unit and rationalization in Belgium. Adjusted operating profit fell 57.9% to €0.7 million and EBITDA was broadly flat at €5.6 million, as weak Belgian infrastructure activity and softer construction markets offset 8.7% environmental-division growth. Net debt rose 25.6% to €27.9 million and leverage increased to 2.4x, largely reflecting renewed IFRS 16 leases; management nevertheless reaffirmed its roughly €110 million FY26 revenue target, citing a stronger order book for H2.

Analysis

ABO’s investable issue is not the reported loss but the quality of the reset: the impairment crystallizes that the legacy drilling model lacked adequate returns, while the remaining model seeks to combine fieldwork with higher-value engineering. That can lift mix and reduce subcontracting over 6-18 months, but the near-term proof burden is high: recurring operating profitability has compressed sharply even before exceptional charges. France is now the key earnings stabilizer; any slippage in its environmental/ecology pipeline would expose the weak Belgian public-infrastructure backdrop.

The balance-sheet risk is more consequential than headline leverage suggests. Lease capitalization explains much of the debt increase, but cash declined while contract assets rose, meaning conversion of work performed into invoicing and cash is the pivotal H2 variable. With a meaningful portion of borrowings maturing by 2027 and variable-rate debt in the stack, weak working-capital release could constrain capex, bolt-on M&A, or shareholder returns even if EBITDA stays broadly stable.

Consensus may over-penalize the one-off charges and IFRS 16 depreciation, but should not blindly capitalize the current environmental-growth narrative: an order pipeline is not revenue, and public-tender delays can shift rather than create demand. The credible rerating catalyst is evidence that H2 growth translates into margin recovery and cash conversion; absent that, the market is likely to value ABO on a lower through-cycle EBITDA multiple due to execution and refinancing risk.

Key Decisions for Investors

• ABO: remain underweight / avoid adding over the next 1-3 months. Upgrade only after evidence of sequential EBITDA-margin expansion and contract-asset conversion; a further decline in operating cash flow or net debt above €30m would falsify a stabilization thesis.
• ABO watch-list long for 6-18 months, not an immediate trade: consider a small position only after FY2026 results demonstrate delivery of revenue guidance plus adjusted operating profit materially above H1’s run-rate. The upside is a mix-driven rerating; downside remains margin stagnation and constrained deleveraging.
• Do not use ABN or ENX as read-through trades. ABN-related litigation has been resolved without an economic linkage to ABN, while ENX has no direct earnings sensitivity to ABO’s operating trajectory.
• Monitor Belgian public procurement awards and French environmental/ecology backlog monthly. A visible restart in Belgian infrastructure can improve utilization rapidly, whereas another quarter of tender deferrals would make the H2 recovery thesis non-credible.